Use of positron emission tomography with [18F] - FDG in oncology: Results in digestive cancers;Résultats dans les cancers digestifs

Bulletin du Cancer

Volumn 90, Issue 2 SPEC. ISS., 2003, Pages

  Bourguet, Patrick ^a   Blanc Vincent, Marie Pierre ^b   Boneu, Andrée ^c   Bosquet, Lise ^b   Chauffert, Bruno ^d   Corone, Carine ^e   Courbon, Frédéric ^c   Devillers, Anne ^a   Foehrenbach, Hervé ^f   Lumbroso, Jean Daniel ^g   Mazselin, Philippe ^f   Montravers, Françoise ^h   Moretti, Jean Luc ⁱ   Talbot, Jean Noël ^h   Avril, Marie Françoise ^g   Banal, Alain ^e   Bey Boeglin, Martine ^j   Bonichon, Françoise ^k   Bugat, Rolland ^c   Bui Nguyen, Binh ^k   Cherel, Pascal ^e   Chevreau, Christine ^c   Fervers, Béatrice ^b   Floiras, Jean Louis ^e   Fournier, Robert ^l   Goldwasser, François ^m   Goupil, Alain ^e   Grahek, Dany ^h   Guillo, Sylvie ^b   Helal, Ourkia ⁿ   Houlgatte, Alain ^f   Lacau St Guily, Jean ^h   Lamy De La Chapelle, Thierry ^o   Pecking, Alain ^e   Périé, Sophie ^h   Reboul, François ^p   Théodore, Christine ^g   Tilly, Hervé ^q   Vaylet, Fabien ^r   Véra, Pierre ^q   Bataillard, A ^b   Bey, P ^s   Borges Paninho, H ^b   Brusco, S ^b   Carretier, J ^b   Debuiche, S ^b   Delavigne, V ^b   Esteves E ^b   Fabre, N ^b   Farsi, F ^t   Gory Delabaere, G ^b   Guy, A G ^b   Haugh, M ^b   Laforet C ^b   Leichtnam, L ^b   Luporsi, E ^u   Philip, T ^t   Renaud Salis, J L ^k   Rope D ^b   Theobald, S ^v   more..

^a CENTRE EUGÈNE MARQUIS   (France)

^b FNCLCC   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f University of Paris Descartes   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL TENON   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j Cabinet du Docteur Fargeon   (France)

^k Intitut Bergonie   (France)

^l Military Teaching Hospital Sainte Anne   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ HÔPITAL ANTOINE BÉCLÈRE   (France)

^o PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^p INSTITUT SAINTE CATHERINE   (France)

^q CENTRE HENRI BECQUEREL   (France)

^r PERCY MILITARY HOSPITAL   (France)

^s INSTITUT CURIE   (France)

^t CENTRE LÉON BÉRARD   (France)

^u CENTRE ALEXIS VAUTRIN   (France)

^v CENTRE PAUL STRAUSS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER DIAGNOSIS; CANCER SCINTISCANNING; COLORECTAL CANCER; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; HISTOLOGY; HUMAN; METASTASIS; NEUROENDOCRINE TUMOR; ONCOLOGY; PANCREAS CANCER; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RECTUM CANCER; REVIEW; STANDARD; STOMACH CANCER; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 17544392772     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Francim. Secrétariat d'Etat à la Santé et le réseau Francim, éd. Le cancer en France: incidence et mortalité. Situation en 1995, évolution entre 1975 et 1995. Paris: 1998.
2. e éd. Paris: FNCLCC, John Libbey Eurotext, 1998. Standards, Options & Recommandations.
3. Bécouarn Y, Blanc-Vincent MP, Lasser P, Dubois JB, Ducreux M, Giovannini M, et al. Adénocarcinome primitif du rectum. In: Fédération nationale des centres de lutte contre le cancer, éd. Cancers digestifs II: pancréas et rectum. Paris: John Libbey Eurotext, 1998; 79-229. Standards, Options & Recommandations, vol. 5.
4. e éd. Paris: FNCLCC, John Libbey Eurotext, 1998. Standards, Options & Recommandations.
5. Luketich JD, Schauer PR, Meltzer CC, Landreneau RJ, Urso GK, Townsend DW, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thor Surg 1997; 64: 765-769.
6. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thor Surg 1997; 64: 770-6.
7. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53: 659-65.
8. Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nuclear Med 2000; 25: 882-7.
9. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nuclear Med 2000; 41: 808-15.
10. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-10.
11. Lightdale CJ. Positron emission tomography: another useful test for staging esophageal cancer [Comment on: J Clin Oncol 2000; 18: 3202-10]. J Clin Oncol 2000; 18: 3199-201.
12. Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thor Surg 2001; 71: 290-4.
13. Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86: 1638-48.
14. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997; 168: 417-24.
15. Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography [Comment in: Ann Surg 2001; 233: 320-1]. Ann Surg 2001; 233: 300-9.
16. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
17. Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thor Cardiovasc Surg 2000; 120: 1085-92.
18. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nuclear Med 1996; 26: 308-14.
19. Nunez RF, Yeung HW, Macapinlac H. Increased F-18 FDG uptake in the stomach. Clin Nuclear Med 1999; 24: 281-2.
20. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999; 19: 61-77.
21. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br J Radiol 1999; 72: 525-9.
22. Hoffmann M, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 1185-9.
23. 18F] FDG PET in gastric non-Hodgkin's lymphoma. Acta Oncologica 1997; 36: 577-84.
24. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85: 1403-6.
25. Seitz JF, Faivre J. La conférence francaise de consensus sur les cancers du côlon: des recommandations simples et précises. Bull Cancer 1998; 85: 293-4.
26. Abdel-Nabi H, Doerr RJ, Lamonica DM, Cronin VR, Galantowicz PJ, Carbone GM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755-60.
27. 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncology Reports 2000; 7: 85-7.
28. 18F-FDG PET detection of colonic adenomas. J Nuclear Med 2001; 42: 989-92.
29. Meta J, Seltzer M, Schiepers C, Silverman DH, Ariannejad M, Gambhir SS, et al. Impact of (18)f-fdg pet on managing patients with colorectal cancer: the referring physician's perspective. J Nuclear Med 2001; 42: 586-90.
30. Wiratkapun S, Kraemer M, Seow-Choen F, Ho YH, Eu KW. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five- year study. Dis Colon Rectum 2001; 44: 231-5.
31. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nuclear Med 2000; 41: 1177-89.
32. Whiteford MH, Whiteford HM, Yee LF, Ogunbiyi OA, Dehdashti F, Siegel, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000; 43: 759-67.
33. Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making? Am J Surg 2000; 180: 1-5.
34. Kalff W, Hicks R, Ware R. F-18 FDG-PET for suspected or confirmed regional reccurence of colon cancer: a prospective study of impact and outcome. Clin Positron Imaging 2000; 3: 183.
35. 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178: 282-7.
36. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989; 170: 329-32.
37. Vitola JV, Delbeke D, Meranze SG, Mazer MJ, Pinson CW. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996; 78: 2216-22.
38. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131: 703-7.
39. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nuclear Med 1997; 38: 1196-201.
40. Ogunbiyi OA, Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Birnbaum, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4: 613-20.
41. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134: 503-11.
42. Zhuang H, Sinha P, Pourdehnad M, Duarte PS, Yamamoto AJ, Alavi A. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver. Nuclear Medicine Communications 2000; 2: 793-8.
43. 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000; 385: 129-34.
44. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001; 21: 1375-8.
45. Johnson K, Bakhsh A, Young D, Martin TE, Arnold M Correlating computed tomography and positron emission tomography scan with operative findings in metastatic colorectal cancer. Dis Colon Rectum 2001; 44: 354-7.
46. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer [Comment in: JAMA 1993; 270: 987-8]. JAMA 1993; 270: 943-7.
47. Desch CE, Benson AB, III, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17: 1312.
48. Consensus conference. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterologie Clin Biol 1998; 22: 205-26.
49. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227: 319-23.
50. Maldonado A, Sancho F, Cerdan J. FDG-PET in the detection of reccurence in colorectal cancer based on rising CEA level: experience in 72 patients. Clin Positron Imaging 2000; 3: 170.
51. Flamen P, Hoekstra OS, Homans F, Van Cutsem E, Maes A, Stroobants S, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer 2001; 37: 862-9.
52. 18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 2001; 8: 779-86.
53. Ito K, Kato T, Ohta T, Tadokoro M, Yamada T, Ikeda M, et al. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nuclear Med 1996; 23: 1372-7.
54. Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C. Scar or recurrent rectal cancer: positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 1989; 124: 197-200.
55. Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De V, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17: 894-901.
56. Topal B, Flamen P, Aerts R, D'Hoore A, Filez L, Van Cutsem E, et al. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur J Surg Oncol 2001; 27: 175-9.
57. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994; 81: 1666-70.
58. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study [Comment in: Ann Surg 2001; 233: 320-1]. Ann Surg 2001; 233: 293-9.
59. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with [f-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002; 20: 388-95.
60. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14: 700-8.
61. Guillem JG, Puig-La Calle J, Akhurst T, Tickoo S, Ruo L, Minsky, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 2000; 43: 18-24.
62. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. Am J Roentgenol 2000; 174: 1005-8.
63. Hannah A, Scott AM, Akhurst T, Berlangieri S, Bishop J, McKay WJ. Abnormal colonic accumulation of fluorine-18-FDG in pseudo-membranous colitis. J Nuclear Med 1996; 37: 1683-5.
64. Meyer MA. Diffusely increased colonic F-18 FDG uptake in acute enterocolitis. Clin Nuclear Med 1995; 20: 434-5.
65. Zervos EE, Badgwell BD, Burak WE, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001; 130: 636-43.
66. Bishof-Delaloye A, Whal RL. How high a level of FDG abdominal activity is considered normal? J Nuclear Med 1995; 36 (Proceedings of the 42nd Annual Meeting of the Society of Nuclear Medicine (suppl.)): 106P (abstr. 430).
67. Miraldi F, Vesselle H, Faulhaber PF, Adler LP, Leisure GP. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nuclear Med 1998; 23: 3-7.
68. Diederichs CG, Staib L, Glatting G, Beget HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nuclear Med 1998; 39: 1030-3.
69. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs, et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000; 20: 109-16.
70. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, et al. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000; 24: 1121-9.
71. Frohlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN. Detection of liver metastases from pancreatic cancer using FDG PET. J Nuclear Med 1999; 40: 250-5.
72. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiology 1999; 54: 248-52.
73. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195: 345-52.
74. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography [published erratum appears in Gut 1995 37: 448]. Gut 1995; 36: 771-7.
75. Bares R, Dohmen BM, Cremerius U, Fass J, Teusch M, Bull U. Ergebnisse der Positronenemissionstomographie mit Fluor-18-markierter Fluordesoxyglukose bei Differentialdiagnose und Staging des Pankreaskarzinoms. Radiologe 1996; 36: 435-40.
76. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nuclear Med 1997; 24: 678-82.
77. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, Delong DM, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. Am J Roentgenol 1998; 171: 1565-70.
78. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999; 229: 729-37.
79. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999; 86: 194-9.
80. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointestinal Endoscopy 2000; 52: 367-71.
81. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JKJ, Pinson, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133: 510-5.
82. 18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver 2000; 20: 487-90.
83. Patel PM, Alibazoglu H, Ali A, Fordham E, Lamonica G. 'False-positive' uptake of FDG in a hepatic adenoma. Clin Nuclear Med 1997; 22: 490-1.
84. Kluge R, Schmidt F, Caca K, Barthel H, Hesse S, Georgi P, et al. Positron emission tomography with [(18)F]fluoro-2-deoxry-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33: 1029-35.
85. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28: 700-6.
86. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-9.
87. Enomoto K, Fukunaga T, Okazumi S, Asano T, Kikuchi T, Yamamoto H, et al. Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma? Kaku Igaku 1991; 28: 1353-6.
88. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-7.
89. Iwata Y, Shiomi S, Sasaki N, Jomura H, Nishiguchi S, Seki S, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nuclear Med 2000; 14: 121-6.
90. 18F-fluotodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 1998; 22: 588-92.
91. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nuclear Med Communications 1998; 19: 641-7.
92. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Quarterly J Nuclear Med 2000; 44: 68-76.
93. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Itoh K, Imamura M, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nuclear Med 2000; 25: 115-9.